Stockholders Approve Massive Dilution for Asset Purchase and Equity Plan
TPST sits 16% above its 52-week low of $2.4 on light trading volume (0.3× avg).
Summary
Stockholders of Tempest Therapeutics approved the issuance of 8.27 million shares for an asset purchase and an increase of 1.41 million shares for the equity incentive plan, leading to extreme dilution for current shareholders.
Key Events · Financing and Capital Events · TPST
-
Massive Share Issuance Approved for Asset Purchase
Stockholders approved the issuance of 8,268,495 shares of common stock for an asset purchase, a transaction valued at approximately $23.06 million based on the current stock price.
-
Significant Equity Incentive Plan Expansion
An additional 1,410,000 shares were approved for the company's equity incentive plan, valued at approximately $3.93 million based on the current stock price.
-
Stockholder Rights Plan Extended
The limited duration stockholder rights plan was extended until October 10, 2026, continuing the existing anti-takeover measure.
-
Annual Meeting Conducted
The company successfully held its 2025 Annual Meeting of Stockholders on January 27, 2026, addressing the Nasdaq non-compliance notice from January 9, 2026, regarding the failure to hold an annual meeting.
Analysis · TPST · Life Sciences
Tempest Therapeutics' stockholders approved the issuance of 8.27 million shares for an asset purchase, a transaction valued at approximately $23.06 million based on the current stock price. This represents a dilutive event significantly larger than the company's current market capitalization. Additionally, 1.41 million shares were added to the equity incentive plan, valued at approximately $3.93 million, further increasing potential dilution. These approvals, while potentially providing capital or assets, will substantially dilute existing shareholders and raise significant concerns about the company's capital structure and future per-share value.
At the time of this filing, TPST was trading at $2.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.7M. The 52-week trading range was $2.40 to $12.61. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.